

Coronavirus (COVID-19) Current Therapy Global Market To Grow At Rate Of -44% Through 2026

The Business Research Company's Coronavirus (COVID-19) Current Therapy Global Market Report 2022: Market Size, Trends, And Forecast To 2026



LONDON, GREATER LONDON, UK, June 2, 2022 /

EINPresswire.com/ -- According to 'Coronavirus (COVID-19) Current Therapy Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026' published by The Business Research Company, the COVID-19 current therapy market size is expected to decline from \$28.16 billion in 2021 to \$16.43 billion in 2022 at a compound annual growth rate (CAGR) of -41.7%. The decline in the COVID-19 current therapy market growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. As per TBRC's COVID-19 current therapy market research, the market is expected to decline to \$1.57 billion in 2026 at a CAGR of -44.4%. The outbreak of the pandemic COVID-19 contributed to the COVID-19 current therapy market growth.

Want to learn more on the COVID-19 current therapy market growth? Request for a Sample now:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3247&type=smp>

The COVID-19 current therapy market consists of sales of drugs currently used for the treatment of COVID-19 infection. The market report includes single-drug therapeutics and combination drug therapeutics used in treating COVID-19 patients. The market consists of revenue generated by the companies that manufacture coronavirus current therapeutics by the sales of these products.

[Global COVID-19 Current Therapy Market Trends](#)

Convalescent Plasma Therapy is used as an experimental therapy to treat COVID-19 patients. The blood plasma of patients who have recovered from a disease is called convalescent plasma (CP). Convalescent Plasma therapy is a type of passive antibody therapy in which blood plasma is

isolated from patients who have recovered from the disease of interest and administered to the patient with severe disease to suppress the virulence and improve clinical symptoms. The blood plasma of recovered COVID-19 patients has antibodies to fight COVID-19 infection.

Global COVID-19 Current Therapy Market Segments

By Drug Type: Remdesivir, Hydroxychloroquine, Ritonavir, Lopinavir, Interferon Beta, Others

By Route of Administration: Oral, Intravenous

By End-User: Hospitals, Clinics, Research Institutes, Others

By Geography: The global COVID-19 current therapy market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America accounts for the largest share.

Read more on the global coronavirus (COVID-19) current therapy market report at:

<https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report>

Coronavirus (COVID-19) Current Therapy Global Market Report 2022 is one of a series of new reports from The Business Research Company that provides coronavirus (COVID-19) current therapy global market overviews, global coronavirus (COVID-19) current therapy market analysis and forecasts market size and growth for the global coronavirus (COVID-19) current therapy market, coronavirus (COVID-19) current therapy global market share, coronavirus (COVID-19) current therapy global market segments and geographies, coronavirus (COVID-19) current therapy global market players, coronavirus (COVID-19) current therapy global market leading competitor revenues, profiles and market shares. The coronavirus (COVID-19) current therapy market report identifies top countries and segments for opportunities and strategies based on market trends and key competitors' approaches.

TBRC's Coronavirus (COVID-19) Current Therapy Global Market Report 2022 includes information on the following:

Data Segmentations: Market Size, Global, By Region and Country, Historic and Forecast, and Growth Rates for 60 Geographies

Key Market Players: Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimune, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Inc., Biocryst Pharma, Gilead Sciences, and Regeneron Pharmaceuticals.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

And so much more.

Looking for something else? Here is a list of similar reports by The Business Research Company:
COVID-19 Drug Associated APIs Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/covid-19-drug-associated-apis-global-market-report>

Remdesivir Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/remdesivir-global-market-report>

COVID-19 Rapid Test Kits Global Market Report 2022

<https://www.thebusinessresearchcompany.com/report/covid-19-rapid-test-kits-global-market-report>

About [The Business Research Company?](#)

The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

The Business Research Company

Email: info@tbrc.info

Follow us on LinkedIn: <https://bit.ly/3b7850r>

Follow us on Twitter: <https://bit.ly/3b1rmjS>

Check out our Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/575038185>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.